The Food and Drug Administration granted breakthrough therapy designation to Omeros Corp.'s (Nasdaq: OMER) immunoglobulin A nephropathy treatment OMS721 lifting the stock price $2.48 to close at $19.58.
Breakthrough designation granted to Omeros
June 13, 2017 at 17:34 PM EDT
